Tempest Outsources Manufacturing for Key CAR-T Candidate Ahead of 2026 Trial
Event summary
- Tempest Therapeutics has selected Cincinnati Children’s Applied Gene and Cell Therapy Center (AGCTC) as a contract development and manufacturing organization (CDMO) for TPST-2003, its dual-targeting CAR-T therapy.
- The agreement focuses on technology transfer and IND-enabling manufacturing, with most activities planned for completion by Q3 2026.
- Interim Phase 1/2a data showed 100% complete response (CR) in six evaluable patients, accelerating the development timeline.
- Tempest intends to file an Investigational New Drug (IND) application in Q4 2026, targeting a U.S. registrational study in 2026.
- TPST-2003 is being developed in China by Novatim, with Tempest holding exclusive rights outside of China, India, Turkey, and Russia.
The big picture
Tempest's reliance on a CDMO for critical manufacturing steps is a common strategy for biotech firms lacking in-house capabilities, but introduces external dependencies and potential delays. The accelerated timeline and promising early data position TPST-2003 as a potential competitor in the crowded multiple myeloma CAR-T landscape, where existing therapies have already generated billions in revenue. The partnership with AGCTC, a recognized leader in CGT CDMO services, suggests Tempest is prioritizing speed and expertise in preparation for a competitive market.
What we're watching
- Execution Risk
- The success of TPST-2003 hinges on AGCTC’s ability to efficiently execute the technology transfer and manufacturing processes within the aggressive Q3 2026 timeline, which could impact the IND filing and subsequent trial initiation.
- Clinical Data
- The upcoming presentation of REDEEM-1 trial data will be critical in validating the interim results and influencing investor sentiment regarding TPST-2003’s efficacy and potential.
- Regulatory Pathway
- The FDA’s receptiveness to a dual-targeting CAR-T approach, particularly given the complexity of manufacturing and potential safety concerns, will significantly shape the trajectory of TPST-2003’s development.
Related topics